Overview

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Antibodies, Monoclonal